Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Joint Mobility Ingredients & Drug Interactions

by 1st Phorm

Capsule Category: Botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Joint Mobility is a dietary supplement by 1st Phorm with 2 active ingredients. Its ingredients are commonly taken for bone fracture healing, joint pain and bone health, weight management.Based on those ingredients, 497 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Paractin, Cissus quadrangularis extract. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Joint Mobility by 1st Phorm

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 2 of its 2 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

Joint Mobility contains 2 active ingredients: Cissus quadrangularis extract and Paractin (andrographis). These are combined in a capsule with inactive ingredients—gelatin, silicon dioxide, and magnesium stearate—that serve as the capsule material and binding agents.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: relieve joint pain and restore mobility.
  • We looked for evidence on: Joint pain, Osteoarthritis, Rheumatoid arthritis (RA), Fractures, tendon health, synovial function.
  • The strongest evidence on file: Andrographis is rated "Possibly Effective" for Osteoarthritis (Natural Medicines).
  • Also on file: Andrographis is rated "Insufficient Reliable Evidence To Rate" for Rheumatoid arthritis (RA).
  • Also on file: Cissus Quadrangularis is rated "Insufficient Reliable Evidence To Rate" for Fractures, Joint pain, Rheumatoid arthritis (RA).

For Cissus quadrangularis, there is possibly effective evidence for weight management in people with obesity. For the other uses listed — cholesterol, bone density, and cancer — the evidence is insufficient to rate.

Andrographis (Paractin) is rated possibly effective for osteoarthritis, sore throat (tonsillopharyngitis), and ulcerative colitis. For familial Mediterranean fever, evidence is insufficient to rate.

The evidence, ingredient by ingredient Cissus Quadrangularis Andrographis

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Cissus quadrangularis is generally well tolerated in short-term use, though long-term safety hasn't been well studied. Reported side effects — headache, insomnia, flatulence, diarrhea, gastritis, and dry mouth — occurred at rates similar to or lower than placebo.

The data advises against use during pregnancy and breastfeeding due to insufficient safety information. Andrographis is often well tolerated short-term, but adverse effects become more likely at high doses (5–10 mg/kg of andrographolide or higher) or beyond 14 days of use.

Common side effects include abdominal discomfort, altered taste, diarrhea, dizziness, fatigue, headache, nausea, rash, and itching. Rarely, severe allergic reactions including anaphylaxis have been reported.

Skin reactions — including Stevens-Johnson syndrome and other serious rashes — have also occurred. The safety data advises against use during pregnancy and breastfeeding.

Side effects, ingredient by ingredient Cissus Quadrangularis Andrographis

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Andrographis, Cissus Quadrangularis.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; immunosuppressants / transplant drugs; diabetes medications.
  • For scale: 497 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Joint Mobility, double-check if you use blood thinners or antiplatelet drugs (Moderate risk of increased bleeding), blood pressure medications (Moderate risk of low blood pressure), or immune-suppressing drugs (Moderate risk of interference). Also verify any diabetes medications, especially glipizide, and NSAIDs like etoricoxib or celecoxib.

Use the checker on this page with your full medication list.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product is intended for joint health through two herbal ingredients with some evidence for osteoarthritis and inflammation. If you take blood pressure medications, blood thinners, diabetes drugs, or immune-suppressing drugs, check this product against your exact medications with the tool on this page before starting — andrographis and Cissus quadrangularis both carry documented risks.

Talk it over with your doctor or pharmacist, especially if you're pregnant, breastfeeding, or planning to use it long-term.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 25, 2021.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Joint Mobility, straight from the product label.

Brand 1st Phorm
Net contents 120 Capsule(s)
Market status On market
Date entered into DSLD Feb 25, 2021
DSLD ID 242860
Product type Botanical
Supplement form Capsule
Dietary claims / uses Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Joint Mobility by 1st Phorm, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
Servings per container
60
IngredientAmount% DV
Cissus quadrangularis extract1000 mg--
Paractin150 mg--

Other ingredients: Gelatin, Silicon Dioxide, Magnesium Stearate

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Targeted synovial rehabilitation formula Relieve pain & discomfort Restore motion & mobility Support joint & tendon health

General Statements

Nothing compares

FDA Statement of Identity

Dietary Supplement

See for yourself

Joint Mobility by 1st Phorm label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Joint Mobility by 1st Phorm

These are the 2 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Cissus quadrangularis extract

Interacts with
86 drugs
1000 mg per serving

Cissus quadrangularis is a traditional vine used mainly for bone health, joint pain, and weight management. Most of the supporting evidence comes from...

Cissus quadrangularis extract monograph & interactions

Paractin

Interacts with
413 drugs
150 mg per serving

Andrographis is a bitter Asian herb traditionally used for colds, flu, and infections, and some studies suggest it may ease cold symptoms and shorten...

Paractin monograph & interactions

Other (inactive) ingredients: Gelatin, Silicon Dioxide, Magnesium Stearate. These complete the product’s ingredient list but are not active constituents.

Interaction report

Joint Mobility by 1st Phorm Drug Interactions

Want to check YOUR meds against Joint Mobility?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
497Drugs
494 Moderate 3 Minor

Ingredients driving the most interactions

Paractin 413

Each ingredient & the kinds of drugs it affects

For each ingredient in Joint Mobility with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Paractin6 drug types · 413 drugs

Anticoagulant/Antiplatelet Drugs

Theoretically, andrographis might increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.
Animal and laboratory studies suggest that andrographis has antiplatelet effects.

Likelihood Possible Evidence D
Antihypertensive Drugs

Theoretically, andrographis might increase the risk of hypotension when used with antihypertensive drugs.
Animal research suggests that andrographis has hypotensive effects.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, andrographis might interfere with the effects of immunosuppressive drugs.
Laboratory research suggests that andrographolide has immunostimulant activity.

Likelihood Possible Evidence D
Celecoxib (Celebrex)

Theoretically, andrographis extract might increase the maximum concentration and time to peak concentration of celecoxib. The clinical significance of these changes is unclear.
Animal research suggests that andrographis extract taken orally increases the maximum concentration and time to peak concentration of celecoxib but does not appear to impact the area under the curve.

Likelihood Possible Evidence D
Etoricoxib (Arcoxia)

Theoretically, andrographis might decrease the absorption of etoricoxib, although the clinical significance is unclear.
Animal research shows that andrographis extract, or the constituent andrographolide, taken orally with etoricoxib decreases the bioavailability of etoricoxib. However, this reduced bioavailability is not correlated with a reduction in the anti-inflammatory effects of etoricoxib in arthritic mice models. The clinical significance of this interaction is unclear.

Likelihood Possible Evidence D
Glipizide (Glucotrol)

Theoretically, andrographis extract might increase the maximum concentration and area under the curve of glipizide; however, opposite effects are seen with the constituent, andrographolide. The clinical significance of this interaction is unclear.
Animal research suggests that andrographis extract taken orally with glipizide in diabetes-induced rats increases the maximum concentration and area under the curve of glipizide. However, the opposite effect is seen with the constituent, andrographolide, in which the maximum concentration and area under the curve are decreased when taken with glipizide.

Likelihood Possible Evidence D

Cissus quadrangularis extract1 drug type · 86 drugs

Antidiabetes Drugs

Theoretically, Cissus quadrangularis might increase the risk of hypoglycemia when taken with antidiabetes drugs.
Small clinical studies suggest that Cissus quadrangularis might reduce fasting blood glucose in individuals with overweight or obesity.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Joint Mobility, from the product label.

1st Phorm

Name
1st Phorm
Pharmacist Counseling Corner

Joint Mobility by 1st Phorm: Common Questions

Does Joint Mobility by 1st Phorm interact with any medications?
Yes. Based on its ingredients, Joint Mobility has a known interaction with 497 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Joint Mobility contains 2 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this if I'm pregnant or breastfeeding?
No. The safety data advises against both ingredients during pregnancy and breastfeeding because there isn't enough data to know they're safe for your baby. Talk with your doctor or pharmacist about whether this product is right for you at this time.
What are the most common side effects?
From andrographis, the most frequent are abdominal discomfort, altered taste, diarrhea, dizziness, fatigue, headache, and nausea — especially at higher doses or beyond 14 days of use. Cissus quadrangularis commonly causes headache, insomnia, flatulence, and diarrhea, though these rates were similar to placebo in trials.
Is this safe to take long-term?
Long-term safety for both ingredients isn't well studied. Short-term use (under 2 weeks) is generally tolerated, but we don't have solid data beyond that. Discuss your plan with your doctor or pharmacist.
Will this help my joint pain or arthritis?
Andrographis (Paractin) is rated possibly effective for osteoarthritis. Cissus quadrangularis doesn't have established evidence for joint or bone problems — the data is insufficient to rate it for those uses.
What if I'm allergic to plants or have a history of rashes?
Andrographis can cause rash, itching, and other skin reactions — rarely severe ones like Stevens-Johnson syndrome. If you've had allergic reactions or serious rashes before, mention that to your doctor or pharmacist before taking this.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Joint Mobility is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Joint Mobility label
Sources

Sources & How We Checked

Joint Mobility's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 31 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Cissus Quadrangularis 5 references
  1. Oben J, Kuate D, Agbor G, et al. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids Health Dis 2006, 5:24.
  2. Oben JE, Ngondi JL, Momo CN, et al. The use of Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis 2008;7:12.
  3. Panpimanmas, S., Sithipongsri, S., Sukdanon, C., and Manmee, C. Experimental comparative study of the efficacy and side effects of Cissus quadrangularis L. (Vitaceae) to Daflon (Servier) and placebo in the treatment of acute hemorrhoids. J Med Assoc.Thai
  4. Nash R, Azantsa B, Kuate D, Singh H, Oben J. The use of a stem and leaf aqueous extract of Cissus quadrangularis (CQR-300) to reduce body fat and other components of metabolic syndrome in overweight participants. J Altern Complement Med. 2019;25(1):98-106
  5. Benjawan S, Nimitphong H, Tragulpiankit P, Musigavong O, Prathanturarug S, Pathomwichaiwat T. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial. Phytomedicine 2022;1 PubMed

See these in context on the Cissus Quadrangularis monograph →

Andrographis 26 references
  1. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  2. Thamlikitkul V, Dechatiwongse T, Theerapong S, et al. Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai 1991;74:437-42.
  3. Zhang CY, Tan BK. Mechanisms of cardiovascular activity of Andrographis paniculata in the anaesthetized rat. J Ethnopharmacol 1997;56:97-101. PubMed
  4. Zhao HY, Fang WY. Antithrombotic effects of Andrographis paniculata nees in preventing myocardial infarction. Chin Med J (Engl) 1991;104:770-5.
  5. Amroyan E, Gabrielian E, Panossian A, et al. Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation. Phytomedicine 1999;6:27-31. PubMed
  6. Zhang C, Kuroyangi M, Tan BK. Cardiovascular activity of 14-deoxy-11,12-didehydroandrographolide in the anaesthetised rat and isolated right atria. Pharmacol Res 1998;38:413-7. PubMed
  7. Puri A, Saxena R, Saxena RP, et al. Immunostimulant agents from Andrographis paniculata. J Nat Prod 1993;56:995-9. PubMed
  8. Melchoir J, Spasov AA, Ostrovskij OV, et al. Double-blind, placebo-controlled pilot and phase III study of activity of standardized Andrographis paniculata Herba Nees extract fixed combination (Kan Jang) in the treatment of uncomplicated upper-respirator
  9. Calabrese C, Berman SH, Babish JG, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 2000;14:333-8. PubMed
  10. Gabrielian ES, Shukarian AK, Goukasova GI, et al. A double blind, placebo-controlled study of Andrographis paniculata fixed combination Kan Jang in the treatment of acute upper respiratory tract infections including sinusitis. Phytomedicine 2002;9:589-97 PubMed
  11. Poolsup N, Suthisisang C, Prathanturarug S, et al. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J Clin Pharm Ther 2004;29:37-45. PubMed
  12. Coon JT, Ernst E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med 2004;70:293-8.
  13. Kligler, B., Ulbricht, C., Basch, E., Kirkwood, C. D., Abrams, T. R., Miranda, M., Singh Khalsa, K. P., Giles, M., Boon, H., and Woods, J. Andrographis paniculata for the treatment of upper respiratory infection: a systematic review by the natural standa
  14. Burgos, R. A., Hancke, J. L., Bertoglio, J. C., Aguirre, V., Arriagada, S., Calvo, M., and Caceres, D. D. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled tria
  15. Saxena, R. C., Singh, R., Kumar, P., Yadav, S. C., Negi, M. P., Saxena, V. S., Joshua, A. J., Vijayabalaji, V., Goudar, K. S., Venkateshwarlu, K., and Amit, A. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis pa
  16. Tang, T., Targan, S. R., Li, Z. S., Xu, C., Byers, V. S., and Sandborn, W. J. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment.Pharmacol Ther 2011;33(2) PubMed
  17. Sandborn, W. J., Targan, S. R., Byers, V. S., Rutty, D. A., Mu, H., Zhang, X., and Tang, T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013;108(1):90-98. PubMed
  18. Melchior, J., Palm, S., and Wikman, G. Controlled clinical study of standardized Andrographis paniculata extract in common cold - a pilot trial. Phytomedicine. 1997;3(4):315-318. PubMed
  19. Balap A, Atre B, Lohidasan S, et al. Pharmacokinetic and pharmacodynamic herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral administration in rats. J Ethnopharmacol. 2016 May 13;183:9-17. PubMed
  20. Bertoglio JC, Baumgartner M, Palma R, et al. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study. BMC Neurol. 2016; 16(1):77. PubMed
  21. Suwankesawong W, Saokaew S, Permsuwan U, et al. Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complement Altern Med. 2014; 14:515. PubMed
  22. Ciampi E, Uribe-San-Martin R, Cárcamo C, et al. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial. BMC Neurol 2020;20(1):173. PubMed
  23. Worakunphanich W, Thavorncharoensap M, Youngkong S, Thadanipon K, Thakkinstian A. Safety of Andrographis paniculata: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2021;30(6):727-739.
  24. More SJ, Tandulwadkar SS, Balap AR, Lohidasan S, Sinnathambi A, Mahadik KR. Effect of Andrographis paniculata extract and Andrographolide on the pharmacokinetics of Aceclofenac and Celecoxib in rats. Futur J Pharm Sci. 2023;9(1):1. PubMed
  25. Sundhani E, Nugroho AE, Nurrochmad A, Puspitasari I, Amalia Prihati D, Lukitaningsih E. Pharmacokinetic Herb-Drug Interactions of Glipizide with Andrographis paniculata (Burm. f.) and Andrographolide in Normal and Diabetic Rats by Validated HPLC Method. M PubMed
  26. Shang YX, Shen C, Stub T, et al. Adverse Effects of Andrographolide Derivative Medications Compared to the Safe use of Herbal Preparations of Andrographis paniculata: Results of a Systematic Review and Meta-Analysis of Clinical Studies. Front Pharmacol 20 PubMed

See these in context on the Andrographis monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring